Literature DB >> 1588924

Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities.

A S Hodge1, D R Humphrey, T L Rosenberry.   

Abstract

Steady state patterns of inhibition of purified human erythrocyte acetylcholinesterase by three inhibitors were analyzed. Edrophonium acted essentially as a competitive inhibitor, whereas tacrine and ambenonium gave mixed competitive and uncompetitive inhibition with acetylthiocholine as substrate. Inhibition constants for the competitive components were 470 microM for edrophonium, 65 microM for tacrine, and 0.12 nM for ambenonium. The extremely high affinity of ambenonium permitted analysis of the rates of approach to steady state inhibition. These rates were characterized by a single exponential time course with rate constants, kexp, that showed a linear dependence when plotted against ambenonium concentration, at fixed substrate concentration. The intercepts of these plots were independent of the substrate concentration and indicated an ambenonium dissociation rate constant of 0.013 +/- 0.002 sec-1. The slope of the plot at the lowest substrate concentration approximated the ambenonium bimolecular or association rate constant and gave a value of 5.2 +/- 0.6 x 10(7) M-1 sec-1. Three models were examined to account for the nearly linear dependence of the slopes of these plots on the substrate concentration. These models indicated that ambenonium and acetylthiocholine competed for a peripheral anionic site in the acetyl-enzyme intermediate formed during substrate hydrolysis. The apparent equilibrium dissociation constant of acetylthiocholine for this peripheral site (1.2-1.4 mM) was significantly different from that calculated from substrate inhibition data (20.1 +/- 2.8 mM). We propose that acetylthiocholine can interact with the acetyl-enzyme both at the peripheral site and at the active site but that only the latter interaction inhibits substrate hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588924

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats.

Authors:  K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

2.  Molecular basis of inhibition of substrate hydrolysis by a ligand bound to the peripheral site of acetylcholinesterase.

Authors:  Jeffrey T Auletta; Joseph L Johnson; Terrone L Rosenberry
Journal:  Chem Biol Interact       Date:  2010-05-21       Impact factor: 5.192

3.  Cholinergic modulation of appetite-related synapses in mouse lateral hypothalamic slice.

Authors:  Young-Hwan Jo; Denise Wiedl; Lorna W Role
Journal:  J Neurosci       Date:  2005-11-30       Impact factor: 6.167

Review 4.  Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Authors:  Deepak Menon; Vera Bril
Journal:  Drugs       Date:  2022-05-31       Impact factor: 11.431

5.  Mechanisms generating dual-component nicotinic EPSCs in cortical interneurons.

Authors:  Corbett Bennett; Sergio Arroyo; Dominic Berns; Shaul Hestrin
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

6.  Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition.

Authors:  Richard R Chapleau; Peter J Robinson; John J Schlager; Jeffery M Gearhart
Journal:  Theor Biol Med Model       Date:  2014-10-02       Impact factor: 2.432

Review 7.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.